Skip to main content
  • Sarkana Pharma Inc.
  • Investment: 2021
  • Status: Active

Sarkana Pharma, Inc. plans to develop, to proof-of-concept, an anti-inflammatory biologic with the potential to treat certain types of auto-immune diseases, including systemic lupus erythematosus (SLE) also known as Lupus. It was originally discovered through one of Eli Lilly and Company’s (Lilly) research and development programs. The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus. Lupus strikes mostly women of childbearing age. However, men, children, and teenagers can also develop lupus.

Involved Team

Dr. Luc Marengère
Managing Partner

Caroline Fortier (CEO)